secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001683168-24-005118
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharmaceuticals in-licenses TPI 287 from Cortice for brain cancer treatment
-------------------------------------------------------------------------------

- CNS Pharmaceuticals entered an exclusive license agreement with Cortice Biosciences for TPI 287, a blood-brain barrier permeable abeotaxane, covering U.S., Canada, Mexico, and Japan.
- Upfront consideration includes 616,698 shares of CNS common stock; future milestone payments up to $100M in cash or shares, plus royalties of 3.0%-7.5%.
- TPI 287 showed 60% objective response rate and 13.4 months overall survival in a Phase 1 trial with bevacizumab in recurrent GBM.
- Company plans to engage FDA in 2025 for a potential registration study of TPI 287 in recurrent glioblastoma.
- Topline results from Berubicin pivotal trial expected in first half of 2025; TPI 287 will leverage existing clinical infrastructure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824005118/0001683168-24-005118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824005118/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer